Optimizing Small-Molecule Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Optimizing Small-Molecule Synthesis
Catalysis for olefin metathesis and aldol reactions and synthetic routes to natural products are some recent gains.


Pharmaceutical Technology
Volume 33, Issue 1, pp. 58-61


(TOP: GLOWIMAGES/GETTY IMAGES FIGURES ARE COURTESY OF MATERIA.)
Underlying the networking between pharmaceutical companies and custom manufacturers gathering at InformexUSA in San Francisco later this month will be the exchange of sound chemistry needed to optimize the synthesis of intermediates or small-molecule active pharmaceutical ingredients (APIs). The success of route selection, process development, and commercial manufacture is specific to a particular compound, but equally important is building scientific critical mass for current and future projects. Some recent approaches include next-generation catalysts for olefin metathesis, polymeric catalysis for aldol reactions, and biomimetic synthesis of natural product-based APIs.

Olefin metathesis


Figure 1: Double ring-closing metathesis in the synthesis of Mercks NK-1 inflammation drug candidate.

Figure 2: Ring-closing metathesis (RCM) and cross-metathesis (CM) in the synthesis of Eisais pladienolide drug candidate.
Olefin metathesis is an efficient method for constructing carbon–carbon double bonds. Recent pharmaceutical applications include work by K.C. Nicolaou, professor of chemistry at the Scripps Research Institute, and his group for the syntheses of a variety of complex biologically active molecules using olefin metathesis as the key step (1). Merck & Co. (Whitehouse Station, NJ) reported the synthesis of an NK-1 inflammation drug candidate in which double ring-closing metathesis was used to build a key spirocyclic intermediate (see Figure 1) (1). Researchers at Eisai (Tokyo) reported the use of both ring-closing metathesis and cross metathesis in the synthesis of pladienolide (see Figure 2). Eisai showed that cross-metathesis was successful when traditional Julia–Kocienski coupling failed to produce the desired product (1).


Patricia Van Arnum
Researchers from Boston College and the Massachusetts Institute of Technology (MIT) recently developed a new catalyst for olefin metathesis that provides selectivity for a broad range of reactions. The researchers, Amir H. Hoveyda, professor of chemistry at Boston College, and Richard R. Schrock, professor of chemistry at MIT and the 2005 Nobel Laureate in chemistry, developed a new chiral catalyst consisting of an enantiomerically pure monodentate aryloxide group bonded to a stereogeneic molybdenum center for alkene metathesis reactions. Enantiomerically pure aryloxide is not commonly used as a ligand in enantioselective catalysis, according to the researchers (2).

The structural flexibility of the catalyst is an important part of its design. "We expect this highly flexible palette of catalysts to be useful for a wide variety of catalytic reactions that are catalyzed by a high-oxidation-state alkydiene species, and to be able to design catalytic metathesis reactions with a control that has been rarely, if ever, observed before," said Schrock in an Nov. 16, 2008 MIT press release.

The researchers applied the catalyst to the enantioselective synthesis of quebrachamine, a natural product alkaloid from the Aspidosperma plant. The quebrachamine was made through an alkene-metathesis reaction using the aryloxide–molybdenum catalyst and achieved an 84% yield with 96% enantiomeric excess (2, 3). The researchers said these results were not able to be achieved with previously reported chiral catalysts (2).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here